Astellas Submits Fezolinetant NDA in Japan for Menopause-Associated Vasomotor Symptoms – Astellas Pharma
7 August 2026 – Astellas Pharma Inc. confirms it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval of… read more.




